$40 Million

Tobira Therapeutics Inc

At-the-market Offering

Developer of antiviral compounds for treating human immunodeficiency virus (HIV) infection. The company develops TBR-652 and TBR-220 antagonists for the treatment of HIV or AIDS, hepatitis and related infectious conditions.